Dipeptidyl peptidase 4 (DPP-4) inhibitors such as sitagliptin are intended for use as monotherapy or in combination with metformin or a thiazolidinedione in patients with T2D as an adjunct to diet and exercise. Sitagliptin should not be used in patients with type 1 diabetes. It has not been studied in patients with a history of pancreatitis who may be at increased risk while using sitagliptin. Heart failure has been observed with other DPP-4 inhibitors.
Learn more about sitagliptin.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Mary L. Windle. Rapid Rx Quiz: Diabetes Drugs - Medscape - May 13, 2022.